Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Salipro to PSDI 2026
2026-10-27
Salipro Biotech is participating in PSDI 2026, the 34th Protein Structure Determination in Industry Meeting, taking place in Marstrand, Sweden, on November 8-10.
Our Senior Scientist, Anne-Sophie Åstrand Tournillon, will be there presenting a poster showcasing the latest cryoEM structures enabled with the Salipro® platform to advance membrane protein research and drug discovery.
If you’ll be there, be sure to stop by her poster and connect with her to learn more about membrane protein research or collaboration opportunities.
We look forward to meeting fellow scientists and industry partners at the event!
Find information about the conference: https://www.psdi2026.com/
Salipro Biotech to BIO-Europe 2026
2026-10-20
Salipro Biotech is attending BIO-Europe 2026!
Our Business Development Manager, Lorena Galán Acosta, is attending BIO-Europe, taking place in Cologne (Germany) on November 9-11.
It's always a great opportunity to meet our partners, exchange ideas and explore new collaborations.
If you're attending and would like to learn more about how the Salipro® platform enables access to native stabilized membrane proteins for applications including structural biology, biophysics, screening and drug discovery, we’d be happy to connect.
Feel free to reach out via the partneringONE platform to schedule a meeting.
See you in Cologne!
New Publication – Insights into Frizzled/WNT Signalling with Salipro®
2026-10-19
Sometimes the lipids are part of the mechanism.
GPCRs are among the most important drug targets, and Salipro® enables their study in native-like lipid environments.
While previous detergent-based structures could not reveal the functional role of PIP2, in this recent preprint the researchers show that this lipid is an integral part of the Frizzled/WNT signaling mechanism itself. By studying the GPCR in Salipro®, the researchers were able to reveal lipid-protein interactions and a mechanism that promotes coupling between Frizzled and its intracellular signaling partner, Dishevelled.
This study also represents one of the first public GPCR structures generated using Salipro®, highlighting the importance of preserving native-like lipid environments when studying membrane proteins.
Congratulations to Gunnar Schulte and colleagues on this exciting contribution to GPCR and structural biology research!
Find the preprint here: G. Schulte, R. Shekhani, M. Scharf, et al., Conserved allosteric regulation of Frizzled-Dishevelled coupling by phosphatidylinositol-bisphosphate, PREPRINT (Version 1) available at Research Square (2026).